Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

CALR mutation burden in essential thrombocythemia and disease outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Désilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 143 (13): 1310–1314.

https://doi.org/10.1182/blood.2023023428

Published: 2024

Includes: Supplemental data

Journal Articles

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Lambert Busque, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Marie-Christine Meunier, Michael Harnois, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2023) 142 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2023-174076

Published: 2023

Journal Articles

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

Valentina Boldrini, Paola Guglielmelli, Giada Rotunno, Chiara Maccari, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Naseema Gangat, Ayalew Tefferi, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2023-189571

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Blood (2023) 142 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2023-186429

Published: 2023

Journal Articles

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, Andrew T. Kuykendall, James M Dolezal, Raffaella Santi, Ling Zhang, Avani M Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Douglas Tremblay, Alexander T Pearson, Mohamed E. Salama, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 901.

https://doi.org/10.1182/blood-2023-173877

Published: 2023

Journal Articles

Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF)

Giacomo Coltro, Raffaella Santi, Giuseppe Gaetano Loscocco, Alessandro Atanasio, Paolo Cicogna, Paola Guglielmelli, Umberto Gianelli, Alessandro M. Vannucchi

Blood (2023) 142 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2023-188726

Published: 2023

Journal Articles

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Paola Guglielmelli, Fiorenza Irushani Vanderwert, Simone Romagnoli, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Laura Calabresi, Giulia Gentili, Giada Rotunno, Niccolò Bartalucci, Valentina Boldrini, Emanuela Sant'Antonio, Danilo Tarantino, Marco Pieraccioli, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 832–833.

https://doi.org/10.1182/blood-2022-156776

Published: 2022

Journal Articles

Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study

Blood (2022) 140 (Supplement 1): 8119–8121.

https://doi.org/10.1182/blood-2022-166039

Published: 2022

Journal Articles

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Blood (2022) 140 (Supplement 1): 1797–1799.

https://doi.org/10.1182/blood-2022-157255

Published: 2022

Journal Articles

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

Giuseppe Gaetano Loscocco, Raffaella Santi, Carmela Mannarelli, Francesco Mannelli, Francesca Gesullo, Giacomo Coltro, Paola Guglielmelli, Umberto Gianelli, Alessandro M Vannucchi

Blood (2022) 140 (Supplement 1): 9714–9716.

https://doi.org/10.1182/blood-2022-167880

Published: 2022

Journal Articles

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Fabiana Pancani, Ilaria Colugnat, Raffaela Aquila, Elena Nacca, Paolo Cicogna, Francesco Passamonti, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 1788–1789.

https://doi.org/10.1182/blood-2022-156781

Published: 2022

Journal Articles

A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, Natasha Szuber, Francesco Mannelli, Animesh D. Pardanani, Curtis A. Hanson, Valerio De Stefano, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 238.

https://doi.org/10.1182/blood-2021-149140

Published: 2021

Journal Articles

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 237.

https://doi.org/10.1182/blood-2021-147869

Published: 2021

Journal Articles

A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis

Giacomo Coltro, Francesco Mannelli, Giuseppe Gaetano Loscocco, Carmela Mannarelli, Giada Rotunno, Chiara Maccari, Fabiana Pancani, Alessandro Atanasio, Ayalew Tefferi, Alessandro Vannucchi, Paola Guglielmelli

Blood (2021) 138 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2021-146600

Published: 2021

Journal Articles

Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera

Alessandra Carobbio, Alessandro Vannucchi, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Ayalew Tefferi, Valerio De Stefano, Elena Rossi, Francesco Ramundo, Arianna Masciulli, Tiziano Barbui

Blood (2021) 138 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2021-146793

Published: 2021

Journal Articles

Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms

Faiqa Farrukh, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Animesh D. Pardanani, Curtis A. Hanson, Valerio De Stefano, Tiziano Barbui, Naseema Gangat, Alessandro M. Vannucchi, Ayalew Tefferi

Blood (2021) 138 (Supplement 1): 3651.

https://doi.org/10.1182/blood-2021-149207

Published: 2021

Journal Articles

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Paola Guglielmelli, MD PhD, Giacomo Coltro, MD, Giuseppe Gaetano Loscocco, MD, Benedetta Sordi, MD, Francesco Mannelli, MD, Chiara Paoli, PhD, Ilaria Marone, PhD, Alessandro Pancrazzi, PhD, Francesca Gesullo, BSci, Carmela Mannarelli, PhD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2018-99-112287

Published: 2018

Journal Articles

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Ayalew Tefferi, MD, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giacomo Coltro, MD, Christy Finke, BS, Giuseppe Gaetano Loscocco, MD, Mythri Mudireddy, MBBS, Benedetta Sordi, MD, Natasha Szuber, MD, Giada Rotunno, PhD, Rangit Vallapureddy, MBBS, Annalisa Pacilli, PhD, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 578.

https://doi.org/10.1182/blood-2018-99-109715

Published: 2018

Journal Articles

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Paola Guglielmelli, MD PhD, Naseema Gangat, MBBS, Giacomo Coltro, MD, Terra L. Lasho, PhD, Giuseppe Gaetano Loscocco, MD, Christy Finke, BS, Benedetta Sordi, MD, Mythri Mudireddy, MBBS, Giada Rotunno, PhD, Natasha Szuber, MD, Annalisa Pacilli, PhD, Rangit Reddy Vallapureddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2018-99-110045

Published: 2018

Journal Articles

Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Tiziano Barbui, MD, Valerio De Stefano, MD, Alessandra Carobbio, MSc, Vincenzo Di Lazzaro, MD, Paola Guglielmelli, MD PhD, Giuseppe Gaetano Loscocco, MD, Alessandra Iurlo, MD PhD, Daniele Cattaneo, MD, Agostino Cortelezzi, Prof, Silvia Betti, MD, Elena Rossi, MD, Maria Chiara Finazzi, MD, Guido Finazzi, MD, Bruno Censori, MD, Mario Cazzola, MD, Elisa Rumi, MD, Marta Bellini, MD, Francisco Cervantes, MD, Eduardo Arellano-Rodrigo, MD, Elena Elli, MD, Maria Luigia Randi, MD, Irene Bertozzi, MD, Martin Griesshammer, MD, Parvis Sadjadian, MD, Francesca Palandri, PhD MD, Nicola Vianelli, Massimiliano Bonifacio, MD, Luigi Scaffidi, Juan Carlos Hernandez-Boluda, MD, Montse Gomez, MD, Emma Cacciola, MD, Rossella Rosari Cacciola, MD, Palova Miroslava, MD, Giuseppe Carli, MD, Eloise Beggiato, MD, Martin H Ellis, MD, Caterina Musolino, MD, Gianluca Gaidano, MD PhD, Davide Rapezzi, MD, Alessia Tieghi, MD, Francesca Lunghi, MD, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 202.

https://doi.org/10.1182/blood.V130.Suppl_1.202.202

Published: 2017

NARROW

CALR mutation burden in essential thrombocythemia and disease outcome

Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome

Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF)

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2 V617F Variant Allele Frequency ≤1%

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

A JAK2 V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis

Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera

Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only